Provided by Tiger Trade Technology Pte. Ltd.

ResMed

222.78
+4.512.06%
Volume:334.58K
Turnover:74.60M
Market Cap:32.14B
PE:21.36
High:225.82
Open:220.95
Low:220.95
Close:218.27
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.39
T/O Rate:0.23%
Dividend:2.40
Dividend Rate:1.08%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.88
PE(LYR):21.36

Loading ...

Resmed - Reiterates Fy2026 Outlook for Non-gaap Gross Margin, Sg&a, R&D, and Non-gaap Tax Rate - SEC Filing

THOMSON REUTERS
·
Jul 08

Resmed Sees 3Q Closing for Matrixcare Divestiture

Dow Jones
·
Jul 08

Frazier to acquire MatrixCare from ResMed, terms not disclosed

TIPRANKS
·
Jul 08

Resmed - Deal Includes Matrixcare, Healthcare First, Citus, and Home Health and Hospice Solutions

THOMSON REUTERS
·
Jul 08

Resmed - to Provide Financial Impact Updates in Q4 Fiscal Year 2026 Filings

THOMSON REUTERS
·
Jul 08

Resmed - to Sell Matrixcare Business to Frazier Healthcare Partners

THOMSON REUTERS
·
Jul 08

Resmed Announces Agreement to Sell MatrixCare Business

GlobeNewswire
·
Jul 08

ResMed offloads software business at massive discount

The West Australian
·
Jul 07

Movement Alert|ResMed Rises 5.01% in Regular Trading, Noctrix Health Acquisition Expands Sleep Portfolio Amid Earnings Anticipation

Market Focus
·
Jul 07

ResMed adjusts ASX CDI levels amid NYSE share activity

TIPRANKS
·
Jul 03

Statement of Cdis on Issue - Rmd-rmd.n

Reuters
·
Jul 03

Resmed to Report Fourth Quarter Fiscal 2026 Results-rmd.n

Reuters
·
Jul 01

Resmed to Report Fiscal Q4 Earnings After NYSE Close

Reuters
·
Jul 01

Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

THOMSON REUTERS
·
Jul 01

Beware Social Security's Dreaded 'tax Torpedo'

Dow Jones
·
Jun 27

Beware the Social Security 'Tax Torpedo' -- Barrons.com

Dow Jones
·
Jun 24

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jun 24

ResMed sets BDR dividend at BRL 0.52 per unit, payable June 24

Reuters
·
Jun 23

ResMed Is Maintained at Overweight by Keybanc

Dow Jones
·
Jun 22

KeyBanc Adjusts Price Target on ResMed to $266 From $290, Maintains Overweight Rating

MT Newswires Live
·
Jun 22